

MIV Therapeutics' First In-Man Study Data 'Very Encouraging', According To SISM Research Morning Note

NEW YORK, Apr 10, 2008 (BUSINESS WIRE) -- (BusinessWire)

(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his "Speculative Buy/4" Rating and 12-18 month target price of \$2.50 for MIV Therapeutics, Inc. (OTCBB: MIVT) in a Morning Note.

The full Morning Note, including important disclosures and disclaimers, is available at <http://www.sism.com> and <http://www.investrendresearch.com>, or may be directly accessed via this link: http://www.investrend.com/Admin/Topics/Articles/Resources/990_1207_829021.pdf. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company. (Due to its length, the URL above may need to be copied/pasted into your Internet browser's address field. Remove any extra spaces if they exist.)

According to analyst Schlotter's Morning Note:

"For any medical device company, approval of its products for use in humans is an enormous corporate development. Currently, MIVT has two CE Mark bare metal stents (BMS) on the market and is targeting one of the fastest growing markets worldwide -- India. After showing excellent results in preclinical studies, MIVT commenced its human clinical trials in May 2007 for its first polymer-free, nanoscale, microporous, hydroxyapatite-based product -- the VESTAsync(TM) Coronary Drug-Eluting Stent System. Excellent safety data, with no Major Adverse Coronary Events (MACE) and good efficacy data in a nine-month follow up of First-In-Man studies were reported on March 31, 2008. This positive study allows MIVT to continue to the next phase of human clinical trials, with the prospect of commercializing its drug-eluting technology within 18 months.

"After a short period of explosive growth, the market for drug-eluting stents (DES) experienced a correction. Uncertainties regarding the risk of late stent thrombosis due to the use of the device led to a decline in the use of DES. MIVT's goal is to restore confidence in drug-eluting stents with VESTAsync(TM) by combining the safety profile of bare metal stents with the efficacy of a drug-eluting stent.

"MIVT is an undiscovered company with a huge opportunity in a very large market. MIVT is significantly undervalued and we reaffirm our "speculative buy" rating and 12-18 month target price of \$2.50."

The company's website is at <http://www.mivtherapeutics.com>.

SISM Research is a private investment research firm, based in Zurich, Switzerland, offering independent, fundamental research on public companies since 1995. SISM Research publishes research on micro- to small-cap companies trading on the OTC, NASDAQ and AMEX. This coverage is geared toward institutional and individual investors in both North America and in Europe.

SISM Research takes steps to ensure independence, including setting fees in advance and utilizing analysts who must abide by CFA Institute Code of Ethics and Standards of Professional

Conduct, the CFA-NIRI Guidelines (<http://www.cfainstitute.org>), the exacting "Standards for Independent Research Providers" (<http://www.firstresearchconsortium.com>) and in accordance with Guidance set forth by U.S. Securities and Exchange Commission's Advisory Committee on Smaller Public Companies at http://www.sec.gov/info/smallbus/acspc/acspc-finalreport_d.pdf. Additionally, analysts may not trade in any security under coverage.

SISM Research was previously paid to provide research coverage for MIVT. That coverage has since expired. This report is not part of that coverage and no fees are associated with this report.

Statements in this announcement that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results.

Complete information about MIVT is also available at the company's dedicated "InvestorPower(TM) Page" accessible from <http://www.investrend.com/company/list.asp?sPathParam=yes>. Anyone interested in receiving alerts regarding MIV Therapeutics research should email firstalert@investrend.com or info@sism.com with "MIVT" in the subject line.

The Investrend Research Syndicate distributes reports published by sources dedicated to unbiased, reliable analytics and complete transparency. The primary measure for determining those sources is the "Standards for Independent Research Providers" (<http://www.firstresearchconsortium.com/standards.html>). The Investrend Research Syndicate is a proprietary entity of Investrend Communications, Inc., a financial intelligence and information firm, serving the financial community with neutral platforms and fundamentally-based material since 1996.

SOURCE: MIV Therapeutics, Inc.

MIV Therapeutics, Inc. Anthony L. Huston, 604-301-9545 ext. 14 Director of Investor Relations ahuston@mivtherapeutics.com www.mivtherapeutics.com or Investrend Research Div. Investrend Communications, Inc. R. Hempel, 212-709-8075 contact@investrend.com www.investrendresearch.com

Copyright Business Wire 2008